PARP Inhibitors in Ovarian Cancer: A Review

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive overview of data for the PARPis olaparib, niraparib, and rucaparib in patients with OC and discusses their role in disease management, w...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Targeted oncology Ročník 18; číslo 4; s. 471 - 503
Hlavní autori:	O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Cham Springer International Publishing 01.07.2023 Springer Nature B.V
Predmet:	Bevacizumab - therapeutic use Biomedicine Carcinoma, Ovarian Epithelial - drug therapy Female Humans Medicine Medicine & Public Health Monoclonal antibodies Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Quality of Life Review Review Article Targeted cancer therapy United States > US
ISSN:	1776-2596, 1776-260X, 1776-260X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!